Compare GoPro Inc (GPRO) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Eli Lilly And Co — how do they compare? GoPro Inc trades at $1.19 (market cap $243.50M), while Eli Lilly And Co trades at $1,162 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 4271× GoPro Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while GoPro Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Eli Lilly And Co for 93 Days on average.
| GPRO | LLY | |
|---|---|---|
Market Cap | $243.50M | $1.04T |
Volume | 11,527,160 | 3,064,878 |
Sector | Technology | Health |
52-Week High | $2.35 | $1.28K |
52-Week Low | $0.58 | $799.57 |
Typical Hold Time | 45 Days | 93 Days |
Enterprise Value | $302.28M | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.22, down 7.58% on the day, as the company faces significant financial challenges with negative net income margins and declining revenues. Despite recent product recognition for its MISSION 1 series, the stock has been volatile amid merger discussions with Starman Optical and influencer investment interest. Technical indicators show a bullish moving average signal but mixed oscillators, while fundamentals reveal persistent losses and cash burn.
The outlook remains highly speculative with a proposed $1.14 per share buyout offering a potential floor, but ongoing losses and competitive pressures pose substantial risks. Analyst sentiment is mixed with only 21% buy ratings, reflecting skepticism about the company's turnaround prospects despite recent merger excitement.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
